EC5026 for Neuropathic Pain in Spinal Cord Injury
This study is testing a new oral tablet called EC5026 for people with neuropathic pain (nerve pain) caused by spinal cord injury. Researchers want to see if EC5026 is safe and well-tolerated, and if it helps with pain. You would take either EC5026 or a placebo (an inactive pill) once daily for 14 days. This study is open to adults aged 18 and older who can provide their own transportation to the study site. The main goal is to check for any side effects within 30 days of treatment. This trial is currently recruiting 36 participants.
- Study design
- This is an interventional study comparing EC5026 to a placebo in 36 participants. It involves two ascending dose regimens of EC5026.
- What's involved
- You would take EC5026 or placebo daily for 14 days, undergo physical exams, vital sign checks, ECGs, blood draws, and complete pain, sleep, and functional status assessments.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and tolerability will be measured for 30 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- William K Schmidt, PhD · STUDY_DIRECTOR · EicOsis Human Health Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]30 days
All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved, stable, or judged by the investigator to be not clinically significant. The Medical Dictionary for Regulatory Activities will be used to code all AEs.